Benjamin T Walters
Overview
Explore the profile of Benjamin T Walters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Walters B, Patapoff A, Kiefer J, Wu P, Wang W
bioRxiv
. 2025 Jan;
PMID: 39868224
We introduce Hydrogen-Exchange Experimental Structure Prediction (HX-ESP), a method that integrates hydrogen exchange (HX) data with molecular dynamics (MD) simulations to accurately predict ligand binding modes, even for targets requiring...
2.
Chitre A, Wu P, Walters B, Wang X, Bouyssou A, Du X, et al.
Nat Commun
. 2024 May;
15(1):3725.
PMID: 38697971
Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of T-cell receptor signaling and as such is an attractive target for cancer immunotherapy. Although the role of the HPK1 kinase...
3.
Cockram P, Walters B, Lictao A, Shanahan F, Wertz I, Foster S, et al.
ACS Chem Biol
. 2023 Dec;
19(1):22-36.
PMID: 38150587
The papain-like protease of SARS-COV-2 is essential for viral replication and pathogenesis. Its location within a much larger multifunctional protein, NSP3, makes it an ideal candidate for a targeted degradation...
4.
Rosenberg S, Shanahan F, Yamazoe S, Kschonsak M, Zeng Y, Lee J, et al.
Cell Chem Biol
. 2023 Feb;
PMID: 36773603
Targeted degradation of proteins by chimeric heterobifunctional degraders has emerged as a major drug discovery paradigm. Despite the increased interest in this approach, the criteria dictating target protein degradation by...
5.
Gamage C, Weis D, Walters B
J Pharm Sci
. 2022 May;
111(8):2210-2216.
PMID: 35533783
Due to significant safety tolerances on maximum levels of visible and sub-visible particles in parenterally dosed drug products like monoclonal antibodies (mAbs), particle formation rates must be determined during development...
6.
Li K, Quinn J, Saabye M, Guerrero J, Nonomiya J, Lian Q, et al.
Anal Chem
. 2022 Jan;
94(2):1230-1239.
PMID: 34990117
With recent advances and success in several drugs designed to treat acute and chronic diseases, targeted covalent inhibitors show a resurgence in drug discovery. As covalent inhibition is time-dependent, the...
7.
Hudgens J, Gallagher E, Karageorgos I, Anderson K, Huang R, Chen G, et al.
J Res Natl Inst Stand Technol
. 2021 Dec;
124:1-7.
PMID: 34877153
No abstract available.
8.
Maun H, Vij R, Walters B, Morando A, Jackman J, Wu P, et al.
Nat Commun
. 2020 Dec;
11(1):6435.
PMID: 33353951
Human β-tryptase, a tetrameric trypsin-like serine protease, is an important mediator of allergic inflammatory responses in asthma. Antibodies generally inhibit proteases by blocking substrate access by binding to active sites...
9.
Ferri E, Le Thomas A, Wallweber H, Day E, Walters B, Kaufman S, et al.
Nat Commun
. 2020 Dec;
11(1):6387.
PMID: 33318494
Inositol-Requiring Enzyme 1 (IRE1) is an essential component of the Unfolded Protein Response. IRE1 spans the endoplasmic reticulum membrane, comprising a sensory lumenal domain, and tandem kinase and endoribonuclease (RNase)...
10.
Izadi S, Patapoff T, Walters B
Biophys J
. 2020 May;
118(11):2741-2754.
PMID: 32416079
Self-association of therapeutic monoclonal antibodies (mabs) are thought to modulate the undesirably high viscosity observed in their concentrated solutions. Computational prediction of such a self-association behavior is advantageous early during...